Repeated intrauterine IgG infusions in foetal alloimmune thrombocytopenia do not increase foetal platelet counts.
OBJECTIVE
Foetal alloimmune thrombocytopenia (FNAIT) is often treated transplacentally with maternally administered i.v. immunoglobulins, but not all foetuses show a consistent platelet increase during such treatment.


METHODS
We retrospectively analysed data from a cohort of ten foetuses with FNAIT treated by direct foetal immunoglobulin infusion. Foetal treatment was begun between 17 and 25 weeks and continued until 36 weeks with weekly cordocenteses and foetal immunoglobulin infusions.


RESULTS
While foetal IgG levels increased steadily during weekly IgG infusions, foetal platelet counts remained unchanged.


CONCLUSIONS
Our retrospective study presents a unique analysis of a historical cohort, contributing to the ongoing debate about the treatment of choice for foetal alloimmune thrombocytopenia.
Giers
G
G
Clinical Hemostaseology and Transfusion Medicine, Düsseldorf, Germany. giers@uni-duesseldorf.de
Wenzel
F
F
Riethmacher
R
R
Lorenz
H
H
Tutschek
B
B
D000328:Adult; D001792:Blood Platelets; D005260:Female; D005315:Fetal Diseases / Q000097:blood / Q000188:drug therapy*; D046128:Fetal Therapies / Q000379:methods; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage*; D010976:Platelet Count; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D012189:Retrospective Studies; D054098:Thrombocytopenia, Neonatal Alloimmune / Q000097:blood / Q000188:drug therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors